CHOSA — Chosa Oncology AB Share News
0.000.00%
Last trade - 00:00- SEK65.48m
- SEK59.85m
- SEK0.00m
Brief: Rhovac Q1 Operating Loss Widens To Sek 7.7 Million
Brief: RhoVac: Signs Of Delays In Ongoing Clinical Phase IIb Study With Drug Candidate RV001 Due To COVID-19
Brief: RhoVac AB Says First Patient In Finland has Started Treatment In BRaVac Clinical Study
Brief: RhoVac Gets FDA Approval In US For Start Of Its Phase IIb Clinical Trial
Brief: RhoVac Receives Approval In Germany And Belgium To Start Clinical Phase IIb Study In Prostate Cancer
Brief: RhoVac Ends Collaboration With Colpman Consulting
Brief: RhoVac Announces Gunnar Gårdemyr New Chairman
Brief: RhoVac Receives Approval In Finland To Start Clinical Phase IIb Study In Prostate Cancer
Brief: Rhovac AB Says Appoints Anders Mansson As New CEO
Brief: RhoVac Granted EUR 2.5 Mln From Horizon 2020
Brief: RhoVac Reports Positive Results From Follow-Up Of Phase I/II Clinical Study
Brief: Rhovac Raises SEK 180.9 Million Through Rights Issue
Brief: Rhovac Publishes Research Results Prior Asco's Meeting
Brief: RhoVac Carries Out Fully Secured Rights Issue Of About SEK 181 Mln
Brief: RhoVac Reports Positive Interim Immune-Results In The Follow-Up Testing
Brief: Rhovac Q2 Pretax Loss Widens To SEK 3.2 Million
Brief: RhoVac: Positive Results In Phase I/II Clinical Study
Brief: RhoVac Reports Positive And Constructive Response From EMA
Brief: RhoVac Announces Rights Issue Of SEK 24.5 Million